Bruton's tyrosine kinase as a drug discovery target
- PMID: 19259548
- DOI: 10.1358/dnp.2008.21.7.1255308
Bruton's tyrosine kinase as a drug discovery target
Abstract
Bruton's tyrosine kinase (Btk) is an important mediator in multiple signal transduction pathways. Fifteen years of research have revealed a complex role for Btk in hematopoietic cells. These studies suggest that Btk may be a promising target for therapeutic intervention for several complicated diseases. Inhibitors targeting the Btk kinase domain have been developed and show clear beneficial effects in animal models of rheumatoid arthritis, lymphoma and other diseases. Here, an overview of these studies is presented with an emphasis on results stemming from medicinal chemistry research.
Copyright 2008 Prous Science, S.A.U. or its licensors. All rights reserved.
Similar articles
-
Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase.ChemMedChem. 2007 Jan;2(1):58-61. doi: 10.1002/cmdc.200600221. ChemMedChem. 2007. PMID: 17154430 No abstract available.
-
Bruton's tyrosine kinase as a molecular target in treatment of leukemias and lymphomas as well as inflammatory disorders and autoimmunity.Expert Opin Ther Pat. 2010 Nov;20(11):1457-70. doi: 10.1517/13543776.2010.517750. Epub 2010 Sep 10. Expert Opin Ther Pat. 2010. PMID: 20831363 Review.
-
Clinical potential of targeting Bruton's tyrosine kinase.Int Rev Immunol. 2008 Jan-Apr;27(1-2):43-69. doi: 10.1080/08830180701784588. Int Rev Immunol. 2008. PMID: 18300055 Review.
-
Imidazo[1,5-a]quinoxalines as irreversible BTK inhibitors for the treatment of rheumatoid arthritis.Bioorg Med Chem Lett. 2011 Nov 1;21(21):6258-63. doi: 10.1016/j.bmcl.2011.09.008. Epub 2011 Sep 10. Bioorg Med Chem Lett. 2011. PMID: 21958547
-
Bruton's tyrosine kinase inhibitors for the treatment of rheumatoid arthritis.Drug Discov Today. 2014 Aug;19(8):1200-4. doi: 10.1016/j.drudis.2014.03.028. Epub 2014 Apr 12. Drug Discov Today. 2014. PMID: 24721226 Review.
Cited by
-
Trivanillic polyphenols with anticancer cytostatic effects through the targeting of multiple kinases and intracellular Ca2+ release.J Cell Mol Med. 2012 Jul;16(7):1421-34. doi: 10.1111/j.1582-4934.2011.01403.x. J Cell Mol Med. 2012. PMID: 21810170 Free PMC article.
-
A phase I trial of PRN1008, a novel reversible covalent inhibitor of Bruton's tyrosine kinase, in healthy volunteers.Br J Clin Pharmacol. 2017 Nov;83(11):2367-2376. doi: 10.1111/bcp.13351. Epub 2017 Aug 1. Br J Clin Pharmacol. 2017. PMID: 28636208 Free PMC article. Clinical Trial.
-
Rilzabrutinib, a reversible covalent Bruton's tyrosine kinase inhibitor: Absorption, metabolism, excretion, and absolute bioavailability in healthy participants.Clin Transl Sci. 2023 Jul;16(7):1210-1219. doi: 10.1111/cts.13524. Epub 2023 Apr 23. Clin Transl Sci. 2023. PMID: 37060187 Free PMC article. Clinical Trial.
-
DrugMap: A quantitative pan-cancer analysis of cysteine ligandability.Cell. 2024 May 9;187(10):2536-2556.e30. doi: 10.1016/j.cell.2024.03.027. Epub 2024 Apr 22. Cell. 2024. PMID: 38653237 Free PMC article.
-
Bruton's tyrosine kinase: from X-linked agammaglobulinemia toward targeted therapy for B-cell malignancies.J Clin Oncol. 2014 Jun 10;32(17):1830-9. doi: 10.1200/JCO.2013.53.1046. Epub 2014 Apr 28. J Clin Oncol. 2014. PMID: 24778403 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources